Build, Buy, or Partner? AI Sourcing Choices in Automotive
- Automotive & Manufacturing
Publishing 26 November 2026
Research brief · HLS-09
Build, buy, or partner? We map how healthcare and life sciences decision units approach this choice: who decides, who can veto, what AI leaders are doing differently, and what it means for the technology partners they buy from.
In healthcare and life sciences, the decision to build, buy, or partner for AI is led by the CIO and the CTO, but the CFO can stop it. In healthcare and life sciences, validation requirements and patient-data rules push many organisations towards partners and validated platforms rather than building from scratch. A typical large healthcare and life sciences organisation involves around 11.1 executives in AI decisions.
In 53% of modelled healthcare and life sciences organisations, the CFO who can veto AI sourcing is a cautious Steward or Sceptic.
Full report: 8 to 10 pages, PDF.
How we label evidence is explained in our methodology.
This brief is planned for 26 November 2026. Request early access and we'll send it to you as soon as it is ready.
Publishing 26 November 2026
Publishing 26 November 2026
Publishing 26 November 2026
Publishing 7 January 2027
Publishing 4 February 2027
One considered briefing a month on how organisations decide on, buy and adopt AI. Unsubscribe at any time.